 Some of the committee's recommendations have been incorporated into drafts of the PDUFA IV bill, which was signed into law in 2007.As of 2011, Risk Minimization Action Plans (RiskMAPS) have been created to ensure risks of a drug never outweigh the benefits of that drug within the postmarketing period.This program requires that manufacturers design and implement periodic assessments of their programs' effectiveness.